CLSA Premium Ltd. (HK:6877)
:6877
Want to see HK:6877 full AI Analyst Report?
Top Page
CLSA Premium Ltd.
(6877)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$0.13
▼(-14.00% Downside)
Action:ReiteratedDate:04/18/26
The score is held down primarily by unstable profitability and weak cash generation (net loss in 2025 and negative operating/free cash flow in 2024–2025). Technicals also point to a downward trend (price below key moving averages and negative MACD). The main offset is a conservatively positioned balance sheet with zero debt, which reduces financial risk but does not fully compensate for earnings and cash-flow volatility.
Positive Factors
Revenue Growth
A 25% revenue rebound in 2025 signals durable market demand and client activity in the firm's core capital-markets services. Sustained top-line growth supports scale, investment in capabilities, and the potential to absorb fixed costs, improving long-term operating leverage if maintained.
Negative Factors
Negative Operating & Free Cash Flow
Repeated negative operating and free cash flows indicate weak cash conversion of reported results and limit internally funded growth or distributions. Persistent cash burn forces reliance on reserves or external financing and constrains strategic flexibility over the medium term unless cash generation improves.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A 25% revenue rebound in 2025 signals durable market demand and client activity in the firm's core capital-markets services. Sustained top-line growth supports scale, investment in capabilities, and the potential to absorb fixed costs, improving long-term operating leverage if maintained.
Read all positive factors
CLSA Premium Ltd. (6877) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$276.53M
Dividend YieldN/A
Average Volume (3M)632.00K
Price to Earnings (P/E)―
Beta (1Y)0.54
Revenue Growth4.13%
EPS Growth-162.50%
CountryHK
Employees13
SectorFinancial
Sector Strength70
IndustryFinancial - Capital Markets
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,033,290,000
10 Day Avg. Volume915,500
30 Day Avg. Volume632,000
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.24
Price to Sales (P/S)2.80
P/FCF Ratio-437.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CLSA Premium Ltd. Business Overview & Revenue Model
Company Description
Top Eminent Healthcare Group Limited, an investment holding company, sells healthcare products and other services in Australia, Hong Kong, and New Zealand....
CLSA Premium Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 106.86M | 86.49M | 191.17M | 39.13M | 5.44M |
| Gross Profit | 40.59M | 28.26M | 34.55M | 4.37M | -13.02M |
| EBITDA | -6.61M | -2.54M | 6.97M | -8.17M | -37.05M |
| Net Income | -7.11M | 11.34M | 9.84M | -31.05M | -56.54M |
Balance Sheet | |||||
| Total Assets | 246.44M | 279.38M | 251.78M | 284.31M | 330.62M |
| Cash, Cash Equivalents and Short-Term Investments | 207.75M | 205.17M | 222.39M | 211.79M | 234.47M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 9.64M |
| Total Liabilities | 5.76M | 35.08M | 11.91M | 53.51M | 61.86M |
| Stockholders Equity | 240.68M | 244.31M | 239.87M | 230.80M | 268.76M |
Cash Flow | |||||
| Free Cash Flow | -683.00K | -19.90M | 1.82M | -16.79M | -40.12M |
| Operating Cash Flow | -656.00K | -19.90M | 1.82M | -16.79M | -39.26M |
| Investing Cash Flow | -27.00K | 9.48M | 9.64M | 1.78M | 2.21M |
| Financing Cash Flow | 0.00 | 0.00 | -1.00K | -2.12M | -10.14M |
CLSA Premium Ltd. Technical Analysis
Negative
0.15
Price Trends
0.15
Negative
0.15
Negative
0.20
Negative
Market Momentum
>-0.01
Positive
33.28
Neutral
39.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6877, the sentiment is Negative. The current price of 0.15 is above the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.15, and below the 200-day MA of 0.20, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 33.28 is Neutral, neither overbought nor oversold. The STOCH value of 39.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6877.
CLSA Premium Ltd. Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$593.19M | 5.92 | 4.26% | ― | -2.41% | 122.45% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
62 Neutral | HK$350.00M | 9.85 | 2.10% | ― | -9.48% | 130.30% | |
50 Neutral | HK$611.16M | 2.72 | 3.24% | 2.39% | -58.31% | 1793.88% | |
48 Neutral | HK$701.66M | 391.06 | 0.83% | 0.33% | -90.06% | -86.21% | |
47 Neutral | HK$276.53M | -42.01 | -1.86% | ― | 4.13% | -162.50% | |
47 Neutral | HK$860.42M | -3.89 | -14.53% | ― | -57.15% | -223.53% |
* Financial Sector Average
HK:6877
CLSA Premium Ltd.
0.14
-0.20
-59.40%
HK:0717
Emperor Capital Group Limited
0.09
0.03
44.26%
HK:0952
China Tonghai International Financial Limited
0.14
-0.04
-23.91%
HK:1461
ZHONGTAI FUTURES Company Limited Class H
0.61
0.11
22.00%
HK:2263
Fu Shek Financial Holdings Limited
0.35
0.18
105.88%
HK:3678
Holly Futures Co. Ltd. Class H
2.81
0.48
20.39%
CLSA Premium Ltd. Corporate Events
Top Eminent Healthcare Sets 2026 AGM to Approve Mandates and Governance Matters
Apr 14, 2026
Top Eminent Healthcare Group Limited has called its annual general meeting for 8 May 2026 in Hong Kong, with a contingency date of 11 May in case of severe weather, to review the audited consolidated financial statements for the year ended 31 Dece...
Top Eminent Healthcare Delays EGM as CSRC Reviews HK$100.3 Million Acquisition
Mar 27, 2026
Top Eminent Healthcare Group has announced that its regulatory filing with the China Securities Regulatory Commission for the HK$100.3 million acquisition of Top Eminent II Limited remains under review, and the company will continue to track the p...
Top Eminent Healthcare Swings to Loss Despite Rising Sales in 2025
Mar 16, 2026
Top Eminent Healthcare Group Limited reported audited results for the year ended 31 December 2025, showing sales of goods from its healthcare business rising to HK$102.25 million from HK$86.49 million a year earlier. Despite this revenue growth, t...
Top Eminent Healthcare Tightens Audit Committee Rules to Meet New Governance Code
Mar 16, 2026
Top Eminent Healthcare Group Limited has updated the terms of reference for its audit committee, reflecting a series of board resolutions dating back to 2012 and most recently incorporating the 2025 Corporate Governance Code enhancements. The revi...
Top Eminent Healthcare Updates Remuneration Committee Governance Framework
Mar 16, 2026
Top Eminent Healthcare Group has updated the terms of reference for its Remuneration Committee to align with the latest Corporate Governance Code under Hong Kong listing rules. The committee must comprise at least three directors with a majority o...
Top Eminent Healthcare Updates Nomination Committee Governance Framework
Mar 16, 2026
Top Eminent Healthcare Group Limited has updated the terms of reference of its nomination committee, reflecting board resolutions passed on 16 March 2026 and earlier amendments in 2017 and 2018. The committee, comprising at least three directors w...
Top Eminent Healthcare Updates Corporate Governance Committee Mandate
Mar 16, 2026
Top Eminent Healthcare Group Limited has updated the terms of reference for its corporate governance committee, reflecting revisions first adopted in 2012 and amended in 2017. The latest changes, reviewed by the committee on 13 March 2026 and appr...
Top Eminent Healthcare to Acquire Online Healthcare Platform in HK$100.3 Million Connected Deal
Feb 27, 2026
Top Eminent Healthcare Group Limited has agreed to acquire 100% of Top Eminent II Limited for HK$100.3 million, in a deal classified as both a major and connected transaction under Hong Kong listing rules. The target group controls PRC entities en...
Top Eminent Healthcare Calls EGM to Approve HK$100.3 Million Acquisition
Feb 27, 2026
Top Eminent Healthcare Group Limited has called an extraordinary general meeting for 30 March 2026 in Hong Kong to seek shareholder approval for the acquisition of all issued shares of Top Eminent II Limited for HK$100.3 million. The proposed deal...
Top Eminent Healthcare Sets March Board Meeting to Approve 2025 Results
Feb 26, 2026
Top Eminent Healthcare Group Limited has scheduled a board meeting for 16 March 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended 31 December 2025. The board will also consider whether t...
Top Eminent flags 2025 loss amid B2C expansion costs
Feb 4, 2026
The company warned of a roughly HK$7.1 million net loss for 2025 versus a HK$11.3 million profit in 2024 after B2C expansion, higher operating and professional costs, and a 71% slide in other income eroded profitability; management expects improve...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.